华熙生物：控股股东已增持211.77万股，完成增持计划逾半

Summary of Key Points Core Viewpoint - The controlling shareholder of Huaxi Biological, Huaxi Xinyu Investment Co., Ltd., is actively increasing its stake in the company, indicating confidence in the company's future performance and potential growth [1]. Group 1: Buyback Plan Details - Buyback Entity: Controlling shareholder Huaxi Xinyu Investment Co., Ltd. [1] - Buyback Period: From August 8, 2025, to February 7, 2026 (6 months) [1] - Total Investment Amount: Between 200 million to 300 million RMB [1] - Maximum Buyback Proportion: Not exceeding 1% of total share capital [1] - Maximum Buyback Price: Not exceeding 70 RMB per share [1] Group 2: Latest Buyback Progress - Implementation Dates: August 27-29, 2025 [1] - Shares Acquired: 2.1177 million shares, accounting for 0.44% of total share capital [1] - Total Investment Amount: 122 million RMB [1] - Progress Completion: Exceeded 50% of the lower limit of the buyback plan of 200 million RMB [1] Group 3: Shareholding Situation - Shareholding Before Buyback: 283.5 million shares, representing 58.86% [1] - Total Shares Held by Concerted Actors: 285 million shares, representing 59.17% [1] - Actual Controller: Chairman and General Manager Zhao Yan [1] Group 4: Future Arrangements - The buyback plan is not yet completed and will continue as planned [1] - Future buybacks will be financed through self-owned or raised funds [1]